Clinical Trial Update: A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and tolerability of PF-03882845 in patients with diabetic nephropathy due to type 2 diabetes. The trial was terminated and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy
• Type 2 Diabetes Mellitus

Drugs mentioned

• PF 03882845

Snippet

Sponsor: Pfizer | Conditions: Type 2 Diabetic Nephropathy | Phase 1 | Status: TERMINATED | Results posted: 2013-09-23